Please login to the form below

Not currently logged in
Email:
Password:

everolimus

This page shows the latest everolimus news and features for those working in and with pharma, biotech and healthcare.

NICE nod for Lilly’s breast cancer drug Verzenio via CDF

NICE nod for Lilly’s breast cancer drug Verzenio via CDF

NICE notes in its guidance that Verzenio and fulvestrant will be an option “where exemestane plus everolimus would be the most appropriate alternative treatment.”. ... On that point, Baroness Morgan said that as everolimus with exemestane is

Latest news

  • Afinitor and Uptravi gain funding from NHS England Afinitor and Uptravi gain funding from NHS England

    Around 70 people in England are currently prescribed everolimus for TSC-related kidney and brain tumours. ... NHS England estimates that a further 300 people in England will benefit from treatment with everolimus for TSC-related refractory epilepsy.

  • $5.76bn deal puts Merck closer to Eisai and fast-growing Lenvima $5.76bn deal puts Merck closer to Eisai and fast-growing Lenvima

    First approved in 2015 for refractory thyroid cancer, Lenvima has subsequently been given the nod as a second-line treatment for renal cell carcinoma in combination with everolimus and has been

  • AAA board presses go on $3.9bn Novartis takeover AAA board presses go on $3.9bn Novartis takeover

    Novartis has no heritage in this type of medicine but already markets two drugs for NET – Sandostatin (octreotide) and Afinitor/Votubia (everolimus) – so the acquisition makes sense from a franchise perspective,

  • NICE U-turn on Novartis' Afinitor for kidney cancer NICE U-turn on Novartis' Afinitor for kidney cancer

    cancer. The U-turn on NICE's 2011 decision comes as the regulator continues its reappraisal of all therapies supported by the Cancer Drugs Fund (CDF), with Afinitor (everolimus) previously only

  • NICE backs Novartis' Afinitor and Pfizer's Xalkori NICE backs Novartis' Afinitor and Pfizer's Xalkori

    Afinitor (everolimus) has been backed as a combination treatment with Pfizer's Aromasin (exemestane) for the treatment of postmenopausal women with HER2-negative hormone-receptor-positive advanced breast cancer - the most ... organs. Prof Carole Longson,

More from news
Approximately 8 fully matching, plus 63 partially matching documents found.

Latest from PMHub

  • Oncology drugs under AMNOG

    patients the comparator was a different targeted therapy, Afinitor (everolimus), rather than Nexavar - although for cytokine-pretreated patients the trial comparator could be used.The G-BA still exercises its right

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

The Exhibition Hall: Past, Present and Future
As I sit here at another pharma conference, I start to reflect on how they have changed over the years....
Success breeds success
This week we received the exciting news that we have been shortlisted for the Times Business Awards 2019, Tunbridge Wells in the 'Best Business 1-25 Employees' category....
Turning learning into action: The challenge of behaviour change
...

Infographics